Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab + MEDI0457 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 89 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov). |
MEDI0457 | INO-3112|INO3112|INO 3112|MEDI 0457|MEDI-0457 | MEDI0457 (INO-3112) is an immunotherapy consisting of DNA plasmids encoding HPV oncoproteins, E6 and E7, along with interleukin-12 (IL-12) (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5525-5525, PMID: 32151670). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03162224 | Phase Ib/II | Durvalumab + MEDI0457 | Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT04001413 | Phase II | Durvalumab Durvalumab + MEDI0457 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Withdrawn | USA | 0 |
NCT03439085 | Phase II | Durvalumab + MEDI0457 | Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers | Active, not recruiting | USA | 0 |